Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 5,934

Document Document Title
WO/2012/157746
The present invention provides a screening method for a preventive or therapeutic agent for an autoimmune disease, comprising evaluating agonist activity or antagonist activity of a test compound on a lysophosphatidylserine receptor usin...  
WO/2012/156351
The present application relates to the field of motor neuron diseases, most particularly to amyotrophic lateral sclerosis and spinomuscular atrophy. Provided herein are strategies to improve symptoms and increase survival in patients wit...  
WO/2012/153191
The present invention provides methods of increasing muscle mass and muscle miochodrial oxidative metabolism. Additionally, the invention provides treating various disorders associated with mitochondrial dysfunction, including but not li...  
WO/2012/153635
The present invention addresses the problem of providing a technique for introducing a PMO of markedly improved cell permeability and of considerably improved introduction efficiency. The present invention thereby addresses the problem o...  
WO/2012/150960
Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA s...  
WO/2012/147597
The present invention addresses the problem of treating camptocormia related to the external abdominal oblique muscle. This problem can be solved by administering a local anesthetic to the external abdominal oblique muscle.  
WO/2012/147470
[Problem] To provide a therapeutic agent which can promote the recruitment of PDGFRα-positive cells such as bone marrow-derived mesenchymal stem cells in blood and the accumulation of the PDGFRα-positive cells in damaged tissues, both ...  
WO/2012/143324
The present invention relates to a method for preparing a cartilage product comprising a protein hydrolysate with a degree of hydrolysis comprised between 0.5% and 3.0%, at least one glycosaminoglycan and at least one growth factor. The ...  
WO/2012/144906
The current invention provides new compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1), spino-cerebellar ataxia 8 and/or Huntington's disease-like 2 caused by expansions of ...  
WO/2012/142459
Disclosed are compounds of Formula I Formula (I) in which n and R1?-R4? are defined herein. Also disclosed is a method of treating spinal muscular atrophy, as well as methods of using such compounds to increase SMN expression, increase E...  
WO/2012/141316
An object of the present invention is to provide a nutritional composition having an effective preventive and/or beneficial effect on reduced muscle mass, decreased basal metabolism, hypothermia, obesity control, visceral fat accumulatio...  
WO/2012/136385
The present invention relates to a compound of formula 1, a pharmaceutical composition containing the compound, a method for its preparation as well as the use of the compound as neuromuscular blocker or skeletal muscle relaxant.  
WO/2012/138223
The present disclosure provides compounds and methods useful in the promotion of muscle growth, the treatment of muscle loss or insufficient muscle growth, and the treatment of fibrotic conditions.  
WO/2012/139093
This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle...  
WO/2012/136385
The present invention relates to a compound of formula 1, a pharmaceutical composition containing the compound, a method for its preparation as well as the use of the compound as neuromuscular blocker or skeletal muscle relaxant.  
WO/2012/138223
The present disclosure provides compounds and methods useful in the promotion of muscle growth, the treatment of muscle loss or insufficient muscle growth, and the treatment of fibrotic conditions.  
WO/2012/136811
The invention relates to a novel skeletal muscle-specific p57 regulatory element. This element is useful to drive and enhance the specific skeletal muscle expression of therapeutic genes. It is therefore provided nucleic acids and vector...  
WO/2012/133942
The present invention provides a method for directly obtaining a pluripotent stem cell from the fat tissue or the umbilical cord of a biological body, and the pluripotent stem cell obtained by means of the aforementioned method. A SSEA-3...  
WO/2012/133896
The purpose of the present invention is to provide a fundamental treatment method for mitochondrial genetic diseases caused by a mutation of mitochondrial DNA, and a pharmaceutical composition therefor. This problem can be solved by a po...  
WO/2012/131656
The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl- vin...  
WO/2012/135736
Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.  
WO/2012/127382
The present invention relates to functional foods comprising DAO and their use for the prevention or treatment of diseases or pathological conditions associated with high levels of histamine in blood, in particular for the prevention or ...  
WO/2012/127381
The present invention relates to a pharmaceutical, cosmetic or dermo-cosmetic composition that comprises DAO, for use in the prevention or treatment of diseases or pathological conditions associated with high levels of histamine in blood...  
WO/2012/127392
The present invention refers to a composition comprising diamine oxidase for use in the prevention or treatment of the symptoms and disorders caused by fibromyalgia or chronic fatigue syndrome.  
WO/2012/124696
[Problem] To provide a compound which is useful as an active ingredient of a pharmaceutical composition, especially of a pharmaceutical composition for the prophylaxis and/or treatment of VAP-1 associated diseases. [Solution] As a result...  
WO/2012/125524
The invention is directed to a composition and associated method for the treatment of musculoskeletal related disorders and diseases. In particular, the present invention provides a class of citrate compounds that can be used to for the ...  
WO/2012/120044
The invention refers to TFEB related molecules, as variants, mutants, truncated proteins,chimeras etc. that are constitutively localized in the nucleus of a eukaryote cell. Such molecules have a therapeutic applicability in all of disord...  
WO/2012/122414
A linear dispensing system is provided that includes a plurality of channels, a pair of parallel rails, a plurality of carriers and a plurality of linear motor modules. The channels are configured to hold inventory products at an orienta...  
WO/2012/120048
The invention refers to TFEB phosphorylation inhibitors. Such molecules have a therapeutic applicability in all disorders that need induction of the cell authophagic/lysosomal system, such as lysosomal storage disorders, neurodegenerativ...  
WO/2012/121403
Problem: An object of the present invention is to provide a drug effective for the treatment of ALS, or a method for treating ALS. Solution: The present invention provides an ALS treatment method that improves clinical symptoms of ALS or...  
WO/2012/119074
The invention generally relates to systems, devices, apparatuses and methods for organizing cells in three-dimensions using matrix stiffness gradients. In particular, the invention relates to systems, devices, apparatuses and methods for...  
WO/2012/116176
Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general formula (I).  
WO/2012/112919
The invention relates to inhibition of SDF-la expression in subacromial bursa cells by CXCR-4 inhibitors. Bursal cell migration in response to SDF-α stimulation is also decreased in the presence of CXCR4 inhibitors. Accordingly, provide...  
WO/2012/112492
This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this inv...  
WO/2012/109296
Embodiments of the present invention are directed generally to antisense compounds and compositions for the treatment of muscular dystrophy, and in particular, Duchenne muscular dystrophy (DMD). In one embodiment, the invention is direct...  
WO/2012/109570
The present invention provides AAV capsid proteins, virus capsids comprising said capsid proteins and virus vectors comprising said capsid proteins, wherein the AAV capsid proteins have one or more mutations, wherein the mutation(s) resu...  
WO/2012/108478
The present invention is a compound represented by formula (I) (in the formula, each of the reference numerals is as recited in the specification) or a salt thereof.  
WO/2012/104823
The present invention relates to pyridopyrimidinone compounds of formula (I) for use in the treatment of neurodegenerative diseases.  
WO/2012/100389
Disclosed are a series of pentacyclic triterpenoid compounds, preparation methods and uses thereof. The compounds have anti-inflammatory, anti-tumor, anti-bacterial and antiviral activities, and they can be used for treating urinary inco...  
WO/2012/100408
A dextrin inclusion complex of total ginsenoside and total flavone of epimedium and the preparation method thereof are disclosed. A pharmaceutical formulation comprising the dextrin inclusion complex and the use of the dextrin inclusion ...  
WO/2012/100050
The present invention relates to a novel composition comprising an implant, scaffold or construct bound to a biological or chemical moiety. The bound moiety has the ability to bind to a component of the extracellular matrix of biological...  
WO/2012/098387
There is provided compounds of formula I, wherein R1, R2, R3 and R4 (and the -CH2-CH2 moiety) have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful i...  
WO/2012/097057
Compositions, methods and kits are provided for modulating the trans-differentiation of cells for example muscle satellite cells. The compositions, methods and kits include a modulator of trans-differentiation of the muscle satellite cel...  
WO/2012/096458
Provided are a process for the preparation of phenyl carbamate derivatives, useful in the treatment of CNS (central nervous system) disorders, an intermediate in the synthesis of the phenyl carbamate derivatives, and a process for prepar...  
WO/2012/097093
The invention provides novel Wnt polypeptides that have enhanced solubility and improved biologic drug-like properties, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used...  
WO/2012/095853
The present invention relates to a pharmaceutical composition for oral administration which comprises an active pharmaceutical ingredient ("API") selected from SIP receptor modulators and agonists, wherein the composition is adapted to p...  
WO/2012/097330
Methods and compositions for treating degenerative muscle conditions are disclosed. The compositions disclosed herein include S1P promoting compositions that include an S1P promoting agent. In certain embodiments disclosed herein, the S1...  
WO/2012/096458
Provided are a process for the preparation of phenyl carbamate derivatives, useful in the treatment of CNS (central nervous system) disorders, an intermediate in the synthesis of the phenyl carbamate derivatives, and a process for prepar...  
WO/2012/097057
Compositions, methods and kits are provided for modulating the trans-differentiation of cells for example muscle satellite cells. The compositions, methods and kits include a modulator of trans-differentiation of the muscle satellite cel...  
WO/2012/097330
Methods and compositions for treating degenerative muscle conditions are disclosed. The compositions disclosed herein include S1P promoting compositions that include an S1P promoting agent. In certain embodiments disclosed herein, the S1...  

Matches 201 - 250 out of 5,934